Application
A. Western blot analysis on (1) Jurkat and (2) Jurkat + Camptothecin using anti-PARP-1 RabMAb (Cat. #AJ1588b), 1:1,000 dilution.Application
B. Flow cytometric analysis of apoptotic and non-apoptotic Jurkat cells using anti-cleaved PARP-1 RabMAb (Cat. #AJ1588b). Jurkat cells were either left untreated (A) or treated with camptothecin (4 uM, 5 hr) to induce apoptosis (B). Cells were fixed and permeabilized, and then stained with anti-cleaved PARP-1. The results indicate that 43% of cells were positive for cleaved PARP (B, M2) after treatment, compared to 9% positive without treatment (A, M2).| Product Name | PARP-1 Antibody (Cleaved p85) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | PARP1, ADPRT, PPOL, Poly [ADP-ribose] polymerase 1, ADPRT;NAD(+) ADP-ribosyltransferase 1;Poly[ADP-ribose] synthetase 1 |
| Clonality | Monoclonal |
|---|---|
| Clone Number | Y34 |
| Host Species | Rabbit |
| Tested Applications | WBFC |
| WB:1:1000~10000 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | ADPRT PPOL |
|---|---|
| Alternative Names | PARP1 ADPRT PPOL Poly [ADP-ribose] polymerase 1 ADPRT NAD(+) ADP-ribosyltransferase 1 Poly[ADP-ribose] synthetase 1 |
| Molecular Weight(MW) | 113084 Da |
| Function | Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. Mediates the poly(ADP- ribosyl)ation of APLF and CHFR. Positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. With EEF1A1 and TXK, forms a complex that acts as a T-helper 1 (Th1) cell-specific transcription factor and binds the promoter of IFN-gamma to directly regulate its transcription, and is thus involved importantly in Th1 cytokine production |
| Tissue Specificity | A synthetic peptide corresponding to residues following the cleavage site of human PARP-1 was used as immunogen. The antibody only recognize p85 cleaved-form of PARP-1. |
| Cellular Localization | Nucleus. Nucleus, nucleolus. |
| Entrez Gene | 142 |
|---|
Application
A. Western blot analysis on (1) Jurkat and (2) Jurkat + Camptothecin using anti-PARP-1 RabMAb (Cat. #AJ1588b), 1:1,000 dilution.
Application
B. Flow cytometric analysis of apoptotic and non-apoptotic Jurkat cells using anti-cleaved PARP-1 RabMAb (Cat. #AJ1588b). Jurkat cells were either left untreated (A) or treated with camptothecin (4 uM, 5 hr) to induce apoptosis (B). Cells were fixed and permeabilized, and then stained with anti-cleaved PARP-1. The results indicate that 43% of cells were positive for cleaved PARP (B, M2) after treatment, compared to 9% positive without treatment (A, M2).| Application Notes | WB:1:1000~10000 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. |
Data sheet for OM216471